Redefining outcomes in immune TTP: an international working group consensus report

Area of Science:

• Hematology
• Immunology
• Thrombotic Microangiopathies

Background:

• Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a critical condition characterized by autoantibody-induced ADAMTS13 deficiency.
• Current outcome definitions for iTTP, established in 2003 and revised in 2017, primarily rely on platelet counts and therapeutic plasma exchange (TPE) timelines.
• These definitions do not account for ADAMTS13 activity levels or the impact of anti-von Willebrand factor (VWF) therapies like caplacizumab.

Observation:

• The International Working Group for TTP (IWG) identified limitations in existing iTTP outcome definitions.
• A novel estimate-talk-estimate approach was employed to develop revised consensus definitions.
• The revised definitions integrate ADAMTS13 activity measurements and consider the influence of anti-VWF therapies.

Findings:

• Updated definitions differentiate clinical remission/relapse (platelet count-based) from ADAMTS13 remission/relapse (ADAMTS13 activity-based).
• Exacerbation and remission criteria are now benchmarked against both TPE and anti-VWF therapy discontinuation.
• Retrospective validation supports the revised definitions, though prospective validation is pending.

Implications:

• The revised definitions offer a more comprehensive assessment of treatment efficacy in iTTP.
• Incorporating ADAMTS13 activity and anti-VWF therapy effects enhances clinical practice and research accuracy.
• These updated criteria are crucial for accurately evaluating patient outcomes and guiding therapeutic strategies in iTTP management.